Pharmacokinetics and Safety/Tolerability of CKD-379

Phase 1

Completed

• Conditions: Type II Diabetes Mellitus
• Interventions: Drug: CKD-379; Drug: D759+D745+D150

• Registration Number: NCT05719155
• Lead Sponsor: Chong Kun Dang Pharmaceutical

Brief Summary

A study to compare the pharmacokinetics and safety/tolerability between CKD-379 tablet and D759, D745, D150 combination

Detailed Description

A randomized, open-label, single dose, 2-period, 2-treatment, crossover study to compare the pharmacokinetics and safety/tolerability of CKD-379 in healthy subjects under fed conditions

Study Timeline

• Status Verified: 2023-01
• Study First Submitted: 2023-01-30
• Study First Submitted QC: 2023-01-30
• Study First Posted: 2023-02-08
• Study Start: 2023-02-27
• Primary Completion: 2023-03-23
• Study Completion: 2023-04-10
• Last Update Submitted: 2023-05-10
• Last Update Posted: 2023-05-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

• Between 19 aged and 50 aged in healthy adult
• 50.0kg≤Body weight≤90.0kg and 18.0kg/m2≤body mass index(BMI)≤27.0kg/m2

Read More

Exclusion Criteria

• Have clinical significant medical history or disease that hepatobiliary system, kidney, nervous system, immune system, respiratory system, digestive system, urinary system, endocrine system(Type I or Type II Diabetes Mellitus, diabetic ketoacidosis etc.), hematological system, cardiovascular system(heart failure, Torsades de pointes etc.), mental illness
• Have clinical significant medical history or disease that urinary tract infection or genital infection including urosepsis, pyelonephritis
• Have a gastrointestinal disease(Crohn's disease, ulcer etc.) history that can effect drug absorption or surgery
• Those who are pregnant or breastfeeding
• Those who are deemed inappropriate to participate in clinical trial by investigators

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Sequence 1	D759+D745+D150	Period 1: Reference drug(D759+D745+D150) Period 2: Test drug(CKD-379)
Sequence 1	CKD-379	Period 1: Reference drug(D759+D745+D150) Period 2: Test drug(CKD-379)
Sequence 2	CKD-379	Period 1: Test drug(CKD-379) Period 2: Reference drug(D759+D745+D150)
Sequence 2	D759+D745+D150	Period 1: Test drug(CKD-379) Period 2: Reference drug(D759+D745+D150)

Primary Outcome Measures

Name	Time	Method
Cmax	0~48hours	Maximum plasma concentration of the drug
AUClast	0~48hours	Area under the concentration-time curve from the time of dosing to the last measurable concentration

Trial Locations

Locations (1)

Seoul National University Hospital; 🇰🇷 Seoul, Jongno-gu, Korea, Republic of